Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: KEGG:D02027 (
Tranilast
)
205
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
We tested the effect of
Tranilast
[N-(3',4'-dimethoxycinnamoyl anthranilic acid)], one of the anti-allergic agents, on the induction of interleukin 2 (IL2) responsiveness of lymphocytes from patients with bronchial asthma or hen-egg allergy following stimulation with Dermatophagoides farinae (Df) or ovalbumin (OVA), respectively. Mononuclear cells pretreated with
Tranilast
for 12 h failed to respond to IL2 following incubation with Df or OVA. Also
Tranilast
inhibited purified protein derivative (PPD)-induced IL2 responsiveness of normal lymphocytes but not the Con A-induced IL2 responsiveness of normal or allergen-sensitized lymphocytes. These results suggested that
Tranilast
has some immunosuppressive effect in that it inhibits antigen-induced IL2 responsiveness. Separation of potential target cells of
Tranilast
disclosed that antigen-presenting adherent cells were more susceptible to
Tranilast
than IL2-responding T-cell rich populations. Expression of
HLA-DR
and -DQ antigens but not DP antigens on macrophages, was significantly suppressed by treatment with
Tranilast
, although
Tranilast
scarcely decreased HLA class II antigens expression on B-cells. The suppression was overcome by interferon-gamma, which was known as an inducer for class II antigen expression. Taken together,
Tranilast
may suppress antigen-induced IL2 responsiveness by inhibiting
HLA-DR
and HLA-DQ antigens on macrophages.
...
PMID:Cell action mechanism of tranilast--effect on the expression of HLA-class II antigen. 769 11